Isolated congenital asplenia (ICA) is the only known human developmental defect exclusively affecting a lymphoid organ. In 2013, we showed that private deleterious mutations in the protein-coding region of RPSA, encoding ribosomal protein SA, caused ICA by haploinsufficiency with complete penetrance. We reported seven heterozygous protein-coding mutations in 8 of the 23 kindreds studied, including 6 of the 8 multiplex kindreds. We have since enrolled 33 new kindreds, 5 of which are multiplex. We describe here eleven new heterozygous ICA-causing RPSA protein-coding mutations, and the first two mutations in the 5'-UTR of this gene, which disrupt mRNA splicing. Overall, 40 of the 73 ICA patients (55%) and 23 of the 56 kindreds (41%) carry mutations located in translated or untranslated exons of RPSA. Eleven of the 43 kindreds affected by sporadic disease (26%) carry RPSA mutations, whereas 12 of the 13 multiplex kindreds (92%) carry RPSA mutations. We also report that six of eighteen (33%) protein-coding mutations and the two (100%) 5'-UTR mutations display incomplete penetrance. Three mutations were identified in 2 independent kindreds, due to a hotspot or a founder effect. Lastly, RPSA ICA-causing mutations were demonstrated to be de novo in 7 of the 23 probands.
Introduction
Isolated congenital asplenia (ICA, MIM271400) is characterized by the absence of a spleen at birth in humans without other developmental defects. It renders otherwise healthy children susceptible to life-threatening invasive infections with encapsulated bacteria, typically Streptococcus pneumoniae, but occasionally Neisseria meningitidis and Haemophilus influenzae b (1, 2). Asplenia can be detected by ultrasound (US) or computed tomography (CT) scans of the abdomen. The associated defect of spleen phagocytic function is confirmed by the detection of Howell-Jolly bodies on a blood smear.
ICA is the only known developmental defect of humans restricted exclusively to a lymphoid organ, as the DiGeorge (3) and Nude (4) syndromes, for example, involve both the thymus and other tissues. A retrospective study in France showed that this condition affects at least 0.51 per 1 million newborns per year (2) . However, the incidence of ICA is probably higher, as individuals with ICA may not present their first severe infection until adulthood (5) , and may be incidentally diagnosed with ICA in the absence of infection (6) (7) (8) (9) . Most cases of ICA are sporadic, but multiplex kindreds exist, and the main mode of inheritance of ICA seems to be autosomal dominant (AD) .
In 2013, we tested the hypothesis of genetic homogeneity underlying ICA in at least some unrelated patients, by looking for rare nonsynonymous variants of the same gene in several patients from different kindreds. Using whole-exome sequencing (WES), we identified seven heterozygous mutations of RPSA in 19 patients from 8 kindreds, among 36 patients from 23 kindreds studied in total (5) . This includes individuals from these kindreds for whom we collected DNA after the publication of our original study. The mutations were located in protein-coding regions and included one frameshift duplication (p.P199Sfs*25), one nonsense (p.Q9*), and five missense (p.T54N, p.L58F, p.R180W, p.R180G, p.R186C) mutations. Mutations of RPSA were more frequent in familial than in sporadic cases, being detected in 6 of the 8 multiplex kindreds (75%) and 2 of the 15 kindreds with sporadic disease (13%). All mutations were private to the ICA cohort, three occurred de novo (p.T54N, p.L58F, and p.R180W), and one (p.R180G) was recurrent, due to a mutational hotspot rather than a founder effect. Complete penetrance was observed in all 8 kindreds, as all 19 individuals carrying a rare heterozygous nonsynonymous mutation of RPSA had ICA. It should be noted that we did not investigate whether synonymous or non-protein-coding mutations in RPSA exons could cause ICA in our previous paper. Moreover, exon 1 of RPSA, which encodes only the 5'-UTR of RPSA, and the part of exon 7 encoding the 3'-UTR were not covered by the exome capture kit used in our previous study.
Since our first description of RPSA mutations in 2013, we have enrolled 37 additional ICA patients from 33 new and independent kindreds. Nine of these 33 kindreds approached us spontaneously after reading about our research online. Our international ICA cohort now comprises 73 patients from 56 kindreds with diverse ancestries and living on four continents (Figure S1 ). Patients were included if they had asplenia or a severely hypoplastic spleen documented by US, CT scan, or autopsy (10) (Table S1, Figure S2 ), and excluded if they had other developmental defects, such as an associated congenital heart malformation (a type of heterotaxy known as Ivemark or asplenia syndrome) (OMIM # 208530). The congenital nature of asplenia is documented at birth in rare cases, occasionally inferred from family history in multiplex kindreds, but is typically suspected in index cases after an episode of invasive infection ( Table S1 ). The protein-coding region of RPSA was analyzed by Sanger sequencing in the 37 newly recruited patients, and we searched for RPSA copy number variation by multiplex ligation-dependent probe amplification (MLPA) in kindreds with no mutations in the protein-coding regions of RPSA.
We also tested the hypothesis that non-coding mutations of RPSA can underlie ICA.
Sanger sequencing was, therefore, performed on exon 1 and the flanking intronic regions (the word 'exon' will hereafter refer to the exon as well as the intronic bases at the intronexon or exon-intron junctions), and the non-protein-coding parts of exons 2 and 7, which encode the 5'-and 3'-UTR of RPSA.
Results

A model for the genetic architecture of ICA caused by RPSA mutations
The field of human genetics has benefited from the recent release of large databases reporting allele frequencies for variants observed in the exomes (123,000) and genomes (75,000) of about 200,000 individuals (11) . These new tools can be used to rule variants out as the cause of a disease on the basis of their allele frequency in the general population. However, several parameters (prevalence, inheritance, penetrance, genetic and allelic heterogeneity) must be taken into account before defining the highest allele frequency in these databases considered plausible for an ICA-causing variant. Based on an estimate of about one in a million children being admitted to hospital for ICA (2) , and the fact that about 40% of individuals with ICA were never admitted to hospital during childhood (10 of the 25 patients that were not on prophylactic antibiotics during childhood, in our cohort) ( Figure 1A , Table S1 ) (5) , we estimate the global prevalence of ICA to be about 1 in 600,000. We found mutations in the protein-coding sequence of RPSA to display complete penetrance for ICA in our previous study, but AD disorders by haploinsufficiency generally display incomplete penetrance (12, 13) . We therefore chose to apply a model of high penetrance but not complete to be conservative and selected 75% penetrance. As variants of RPSA were shown to be the genetic cause of ICA in eight of 23 kindreds in our previous study, we estimated the RPSA gene to be responsible for about 30% of ICA cases (genetic heterogeneity of 0.3). We observed the same mutation twice in the eight ICA kindreds with RPSA mutations. We therefore hypothesized that a single mutation could explain up to 25% of the ICA kindreds (allelic heterogeneity of 0.25).
Using these estimates, we were able to calculate a maximum plausible allele frequency for an ICA-causing variant in a monoallelic dominant model, as follows: _ = * +,,,,,, × 0.25 × 0.3 × * ,.56 × * 7 = 8.33x10 -8 (14) . Therefore, in our monoallelic model, the maximum tolerated allele count for an ICA-causing variant in the two combined and complete databases (~200,000 individuals) would be 0 (95% confidence interval). The maximum tolerated allele count for an ICA-causing variant in these databases restricted to WGS (75,000 individuals) would also be 0. The seven nonsynonymous mutations identified in our 2013 study (5) are absent from the gnomAD and Bravo databases (accessed in February 2018), and, therefore, meet these criteria.
Identification of previously unknown protein-coding mutations in RPSA
We therefore hypothesized that nonsynonymous variants of RPSA absent from gnomAD and Bravo would be present in about a third of the newly recruited kindreds ( Figure S1 ). Sanger sequencing of the protein-coding region of RPSA was performed for the 33 newly recruited kindreds. We identified eleven heterozygous coding mutations, in ( Figure S3 ). Mutation p.R180Q is recurring in 2 families, but we were not able to analyze the full haplotype around the mutation in family ICA-BO. Finally, we performed MLPA in the remaining kindreds, to detect copy number variations overlapping with the protein-coding region of RPSA. No copy number variations were identified (see Methods). The overall proportion of ICA kindreds carrying protein-coding mutations of RPSA (12 of the 33 new kindreds) is consistent with both our previous report (8 of the 23 previous kindreds) and our model for the genetic architecture of RPSA mutations underlying ICA.
The ICA cohort is enriched in RPSA protein-coding mutations
We then tested the hypothesis that these very rare nonsynonymous mutations of RPSA caused ICA, by comparing their frequency in the ICA cohort and the general population (15) . The gnomAD and Bravo databases were considered the most suitable for such an RPSA-burden test as, together, they contain sequencing information for about 375,000 chromosomes, and the exome and genome sequences they contain provide good coverage of the protein-coding region of RPSA. We restricted our search to mutations of RPSA absent from the combined gnomAD and Bravo data, based on our previous estimates. Thus, for the calculation of RPSA burden, we considered only mutations that passed the quality filter and were present on no more than one chromosome in gnomAD and Bravo for our original comparison. We did not restrict our analysis to a specific population, as our cohort is diverse and the variants compared are extremely rare. We found that the newly recruited ICA kindreds, and the entire ICA cohort, were significantly enriched in very rare nonsynonymous variants, relative to the general population (p=2.44x10 -31 and p=9.95x10 -51 respectively) ( Table S3 , Figure S4 ). The end of the RPSA sequence is less strongly conserved than the rest, so the frameshift of the last 60 amino acids, and the p.Q283* mutation removing the last 12 amino acids may have little effect. Overall, these results confirm our original observation that very rare non-synonymous mutations of RPSA cause ICA in about a third of the ICA kindreds. *: statistical significance threshold after correction with the stringent Bonferroni correction: 2.5x10 -6 (in our 2013 study, we looked at 4,222 genes and therefore we originally used a p-value cutoff of 1.2x10 -05 ) **: statistical significance threshold: 0.05. & : Non-synonymous variants were defined as nonsense, stop-loss, frameshift indels, inframe indels, missense, essential splice and splice variants affecting exons 2 to 7. Splice variants affecting only exon 1 were not taken into account for the calculation concerning non-synonymous variants, because exon 1 is non-coding, but they were analyzed in the UTR burden test ( Table 2 ). All of the variants used in the gene-burden tests are presented in Tables S2 to S5.
Incomplete penetrance of some novel protein-coding RPSA mutations
Unlike that of the original RPSA protein-coding mutations reported in 8 ICA families (5), the penetrance for ICA of the mutations in 6 of the 12 new kindreds (50%) with new protein-coding mutations of RPSA was incomplete ( Figure 1C) . Fifteen individuals carrying an ICA-causing mutation were found to have structurally and functionally normal spleens based on abdominal US or CT scans and/or the absence of Howell-Jolly bodies on blood smears. The distribution of these 15 asymptomatic carriers of RPSA mutation was as follows: p.A21P (1 of 3 carriers), p.G26S (1 of 3), p.M34V (1 of 2), p.[I65I;V66F] (9 of 11), p.Q84R (1 of 2), and p.V197Sfs*26 (2 of 3). We hypothesized that the nature of the RPSA mutation (e.g. its biochemical impact) contributes to the penetrance of ICA. We compared the Combined Annotation Dependent Depletion (CADD) scores of the mutations with their penetrance for ICA. CADD scores take into account information about evolutionary conservation, gene regulation, and transcription, to calculate the extent to which a nucleotide change is likely to be deleterious (see Methods) (16) . There was no significant difference between the mean CADD of incompletely penetrant compared with fully penetrant RPSA mutations (mean CADD 25.8 vs. 29.4, p-value=0.58 (Figure 2A, Figure S4 ). Similarly, other deleteriousness predictors did not show significant differences between the two sets of variants ( Figure S5 ). We then mapped positions of the human mutations onto the human crystal structure of the small ribosomal subunit (Figure 2B ) (17) . All five missense mutations with incomplete penetrance were found to be located outside of the hydrophobic core of RPSA lined with two a-helices ( Figure 2C, 2E) . Amino acid 180, a mutational hotspot in ICA modified in 5 of 14 families with completely penetrant RPSA mutations, contacts the nearby a-helix and seems to stabilize the core (Figure 2C, 2D) . Moreover, all seven missense mutations with complete penetrance caused a change in the polarity or charge of the amino-acid side-chain group, whereas p.M34V and p.V66F did not. These findings suggest that the incomplete penetrance of nonsynonymous mutations of RPSA may be due to the residual function of the protein, but further studies are required to understand the difference in penetrance of different RPSA mutations.
Identification of mutations in the non-protein-coding region of RPSA
We hypothesized that some cases of ICA may result from mutations in the noncoding region of RPSA exons. We searched for mutations in the 5'-UTR and 3'-UTR of RPSA, which are poorly covered by most WES kits. The 5'-and 3'-UTRs were subjected to Sanger sequencing in all 36 ICA kindreds of our cohort without very rare nonsynonymous mutations of RPSA. As for the candidate ICA-causing protein-coding mutations, we considered only mutations not present in gnomAD and Bravo. We identified two mutations predicted to affect the splicing of the 5'-UTR of RPSA that were private to our ICA cohort in three kindreds (Figure 1D ). There were no very rare or private 3'-UTR mutations. One mutation, c.-34+5G>C (canonical ENST00000301821 transcript), was recurrent. It was identified in both a multiplex kindred (ICA-G) and a patient with sporadic disease (ICA-BD). Another mutation, c.-39_-34+3del (ENST00000301821), was identified in a patient with sporadic disease (ICA-AO). These two mutations were absent from the 
Enrichment of the ICA cohort in RPSA non-coding mutations
We tested the hypothesis that these very rare non-coding mutations of RPSA cause ICA, by comparing their frequency in the ICA cohort and the general population. In total, 26 chromosomes carried a very rare RPSA 5'-UTR variant (1 chromosome in gnomAD WGS and Bravo, Table S4 , Table S5 ). Fisher's exact tests indicated that very rare mutations in the 5'-UTR or 3'-UTR of RPSA were more frequent in the ICA cohort than in the general population (p=9.75x10 -06 ; Table 2 ). These results suggest that the very rare noncoding mutations identified in ICA patients may cause ICA. We also identified a 5'-UTR variant (c.-47C>T) in three unrelated Western European families that was absent from the gnomAD database but present in Bravo, with an allele frequency of 3.9x10 -05 . This variant was not retained as potentially disease-causing in our study, due to its allele frequency, but it might have a modifying effect (see discussion). The two kindreds carrying the c.-34+5G>C mutation were both from the United Kingdom. This mutation is not present in the UK10K dataset (18) corresponding to high-quality WGS data for 3,781 samples. We investigated whether this very rare variant was recurrent due to a founder effect or a mutational hotspot. We defined the haplotypes encompassing this mutation in both kindreds. We identified an 850 kb region with a haplotype of 250 SNPs common to the two kindreds. The length of this common haplotype strongly suggests that the mutation was inherited through a founder effect in both kindreds. Using ESTIAGE (19) , we estimated the most recent common ancestor (MRCA) to have occurred 163 generations ago (CI95%= 52-743). Assuming a generation time of 25 years, the MRCA was estimated to have lived 4,075 years ago (CI95%= 1300-18575). The ICA cohort is, thus, enriched in private 5'-UTR mutations, one of which is present in two distantly related families, with incomplete penetrance. All very rare UTR mutations 51 3 2.58x10 -6 3 9.75x10 -6 *: In this analysis, the 5'-UTR and 3'-UTR of RPSA are studied because RPSA is a candidate gene based on the protein-coding mutations in the same gene. This type of mutations was not studied in our initial cohort in 2013. Therefore, statistical significance threshold is set at 0.05. Statistical significance threshold after correction with the stringent Bonferroni correction is: 2.5x10 -6 .
Functional impact of the RPSA 5'-UTR mutations
We investigated whether these 5'-UTR mutations were responsible for ICA, by studying their functional impact. The 5'-UTR of RPSA is not generally well conserved ( Figure S5) . However, the two mutations found in our ICA cohort are located at positions chr3:39,406,769 (hg38) and chr3:39,406,759-39,406,767, which are highly conserved between 100 vertebrate species (Figure S6) (18) . This suggests that the 5'-UTR mutations identified in ICA patients may have a functional impact (Figure S4) . We then used computational tools to construct hypotheses concerning the potential functional impact of these 5'-UTR mutations. The c.-34+5G>C mutation was predicted to impair splicing at the exon1/intron1 junction by disrupting the acceptor site (method: NNsplice9.0 (20) ).
The c.-39_-34+3del mutation eliminates the exon1/intron1 splicing junction and would, therefore, also be predicted to impair the splicing of intron 1. NNsplice9.0 predicted that the next splicing site would be 70 base pairs further downstream. We also estimated the potential impact on splicing of the other 5'-UTR variants present in gnomAD or Bravo.
Only two of these 52 variants were predicted to impair splicing, both disrupting the acceptor splicing site for the intron1/exon2 junction (Table S6 ). We then experimentally tested the hypothesis that these ICA-associated 5'-UTR mutations impair splicing. RNAseq (Figure 3A) . The two 5'-UTR mutations lead to a 50% wild-type:50% mutant allelic ratio (Figure 3B) . These 70 or 67 extra nucleotides contain two potential ATG codons (Figure S7) . We also performed TOPO-TA cloning on cDNAs generated from peripheral blood mononuclear cells (PBMCs) from kindred ICA-G (c.-34+5G>C) (Figure S8) . Again, we found that the c.-34+5G>C mutation prevented correct splicing at the exon 1/intron 1 junction, creating an insertion of 70 bp at the end of exon 1. Both splice mutations of the 5'-UTR thus impair the structure but not the stability of the mRNA, contrasting with the completely penetrant p.D73Vfs*16 mutation, for which no RPSA transcript carrying the mutation (0/67) was identified by TOPO-TA cloning, likely due to nonsense-mediated decay. Overall, these results suggest that rare mutations with a significant impact on the 5'-UTR of RPSA probably cause ICA, with incomplete penetrance.
Discussion
We identified eleven new protein-coding mutations and the first two non-coding mutations of RPSA responsible for ICA. Mutations in RPSA exons underlie ICA in 41% of index cases and kindreds (23 of 56 kindreds). This proportion differs significantly between multiplex kindreds (such mutations were found in 12 of 13 multiplex kindreds; 92%) and kindreds affected by sporadic ICA (11 of 43 kindreds; 24%). Mutations in RPSA exons were found to cause ICA in about half the patients (40 of 73) from the 56 kindreds included in our international ICA cohort. All of the mutations identified were not present in any variant database we looked at, which included more than 375,000 chromosomes. The burden of de novo RPSA mutations was high, with at least 7 of the 23 probands in kindreds with RPSA mutations carrying a de novo RPSA mutation. These results build on our previous report (5) The distinctive features of developmental tissues observed in the ribosomopathies underlying ICA and DBA, and emerging studies in other organisms suggest that the ribosome may influence the temporal and spatial control of gene expression during development. In an elegant study, lower amounts of ribosomes were shown to preferentially alter the translation of some transcripts, such as GATA1, thereby impairing erythroid lineage commitment and underlying DBA (28, 29) .
Variable clinical expression, between patients and kindreds, of red-cell aplasia and congenital malformations has been widely reported for DBA (30, 31) . The DBA-causing mutations of RPS19 resulting in a severe clinical phenotype typically occur at a 'mutation hot spot' in the core of the protein, which has a structure consisting of five a-helix bundles organized around a central amphipathic a-helix (32) . In RPSA, arginine in position 180 is a hotspot for ICA-causing mutations, and is also part of the core of the RPSA protein. We identified five completely penetrant mutations at the codon coding for R180.
Incompletely penetrant mutations for both conditions map outside the core of the protein (Figure 2C-E) . Moreover, the first exon of RPS19, like that of RPSA, is untranslated (5'-UTR) and the start codon is located at the start of exon 2. In addition to essential splice site mutations, one or two nucleotides downstream from the start codon of RPS19 (33), rare 5'-UTR DBA-causing variants of RPS19, resulting in a longer 5'-UTR, have been shown to reduce RPS19 protein levels by 20%, modifying translational efficiency in a tissuespecific manner (34) . The parallel between the RPSA mutations underlying ICA and the RPS19 mutations underlying DBA is striking. In both cases, variants of both translated and untranslated regions of the exons can be disease-causing, and both types of mutations can show incomplete penetrance.
Methods
Patients
The 10% of the population, a frequency several orders of magnitude greater than that of total asplenia (35) . As we have more than 50 kindreds enrolled in our cohort, we would expect there to be at least a few kindreds including individuals with an accessory spleen. We therefore decided not to consider these individuals as cases during familial segregation studies, and the absence of an RPSA mutation in these individuals would therefore not rule out the involvement of the mutation in ICA in other family members. In addition to studying the newly recruited families, we also updated the information for families reported in 2013. First, a newborn in family A was diagnosed with ICA. This baby carries the same missense mutation, p.R180G, as his relatives with ICA. Second, one patient, ICA-M-01, wild-type for RPSA has recently been diagnosed with Fanconi anemia, and we have identified compound heterozygous mutations of FANCA. Third, a sporadic boy (ICA-AH) has been found to carry a mutation in ATRX, which has been associated with asplenia as part of a broader syndrome in the past. He also suffers from mental retardation. We have retained these two kindred in all of the calculations in this paper to ensure consistency with our first report. Finally, the reader may note several gaps in the 'numbering' of the kindreds. For example, there is no kindred ICA-BA or ICA-BB, but there is an ICA-BC kindred. These gaps correspond to families or patients that have contacted us but that were not included in this study, for diverse reasons such as a lack of availability of DNA samples or of a signed informed consent form.
Sanger sequencing of the seven exons of RPSA
In addition to the primers used for sequencing exons 2-7, as described in our previous paper (5), we designed primers to sequence the 5'-UTR/exon 1 of RPSA. We also included an M13 sequence in all primers (exons 1-7), to decrease the sequencing time. Primer-BLAST (www.ncbi.nlm.nih.gov/tools/primer-blast) was used to check that the primers would not amplify another sequence from the human genome. Following the isolation of genomic DNA from EBV-B cells or PBMCs from patients and their relatives, each of the seven exons of RPSA was sequenced with these primers (listed below). 
Allele frequencies
The allele frequencies of RPSA variants present in the general population were retrieved from the exome and genome information in two public databases (last accessed 
Estimation of AF for ICA
Maximum tolerated reference allele counts were calculated with the Frequency Filter available from URL: https://cardiodb.org/allelefrequencyapp/. Based on the findings published in our first report, we predicted that ICA-RPSA would display monogenic inheritance, an incidence of about 1/600,000, an allelic heterozygosity of 0.25, a genetic heterozygosity of 0.3 and a penetrance of 0.75. Confidence was set at 0.95 and the reference population at 400,000 alleles.
Gene burden tests
All the data from public databases was downloaded on 20 February 2018. All variants with an impact on the canonical transcript ENST00000301821 were analyzed. Bravo and gnomAD differ in their representation of ENST00000301821, particularly at the end of exon 3. We used the gnomAD representation, which is identical to the Ensembl description. We also used the Liftover tool (https://genome.ucsc.edu/cgi-bin/hgLiftOver) to facilitate comparisons between the two databases. We converted the GnomAD hg19 coordinates into hg38 coordinates, and performed manual checks to ensure that this process did not introduce any errors.
Based on our model, we focused principally on variants present on only one chromosome in the public databases. However, about 3,000 whole-genome sequences are present in both gnomAD and Bravo. We therefore decided to retain a variant that was present on one chromosome in Bravo and one chromosome in gnomAD. However, we counted it as occurring on only one chromosome in this case (1+1=1). Other variants present on two chromosomes in either database were systematically filtered out (2+0=0).
Nonsynonymous variants were defined as nonsense, stop-loss, frameshift, missense, essential splice and splice variants affecting exons 2 to 7. Splice variants affecting only exon 1 were not taken into account for the calculation concerning non-synonymous variants, because exon 1 is non-coding, but they were analyzed in the UTR burden test.
Moreover, the whole-exome sequences of the gnomAD database do not cover this region.
The c.*3_25delTGTTCTTGCATAGGCTCTTAAGC mutation was not taken into account for the loss-of-function variant burden test, as the deletion results in the same 295 amino acids and termination codon. All of the variants used in the gene-burden tests are presented in supplementary tables (Tables S2 to S5) .
We restricted our RPSA-burden tests to variants that passed the quality filter in gnomAD and Bravo, as most of the low-quality variants are false positives (36) . Fisher exact tests were performed with R software:
input2.df = matrix (c(a,b,c,d) , nrow = 2) p_val = fisher.test(input2.df)$p.value.
Multiplex ligation-dependent probe amplification (MLPA) for CNV detection
We also searched for losses of one copy of RPSA as a cause of haploinsufficiency. We used the multiplex ligation-dependent probe amplification (MLPA) method, which has proved successful for the detection of CNVs in DBA (37) . We designed probes mapping at least partly to the intronic region, because RPSA has several pseudogenes. As controls, we used probes binding to chromosomes 18, X and Y. We also designed a probe binding upstream from exon 1 to cover a region including a 21 bp deletion SNP (rs199844419) that would impair the binding of the probe, as a proxy for a control for the loss of one copy of RPSA.
Three individuals in our cohort are heterozygous carriers of this SNP. No kindred presented a loss of one copy of one RPSA probe except for the probe upstream of exon 1 in the individuals carrying the 21bp deletion. We also searched the ExAC database -All of the probes are then mixed and diluted using the volumes in the table below to prepare the Synthetic Basic Probemix.
-gDNA from individuals to be studied (100-150ng) was resuspended in a total of 5µl TE, and denatured (98°C, 5'; 25 °C, 5').
-Synthetic Basic Probemix (1.5µl) and MLPA buffer (1.5µl) were added to the denatured gDNA and incubated at 95°C for 1' followed by 60°C for 16-20 hours for hybridization. A 32µl of ligase mix buffer was then added to the mix for a 15' incubation at 54°C, followed by an inactivation step (98°C, 5'). Amplification of the ligated products is performed by adding 10 µl of PCR mix (SALSA PCR) followed by PCR amplification for 35 cycles (95°C, 30"; (60°C, 30", 72°C, 1') x35; 72°C, 20'; 15°C).
-The separation of fragments by capillary electrophoresis were performed mixing 1µl of undiluted PCR product to 9.0µl formamide and 0.2µl LIZ standard, and then denatured at 85°C for 2' and hold at 4°C for a minimum of 5' before analyzing using a ABI-3730 DNA Analyzer.
RPSA haplotypes investigated by microsatellite analysis (de novo)
We determined whether the samples sequenced in kindreds in which RPSA mutations appeared de novo were of the expected origin (i.e. the sample labeled as the father indeed corresponded to DNA from the father, and that labeled as the mother indeed corresponded to the DNA of the mother. In other words, we checked that the parentchild relationships between the subjects were as indicated by the family, and that there was no mixing up of the tubes at any point during the study). This was necessary to determine whether RPSA mutations truly occurred de novo in the ICA-AN, ICA-AT, ICA-AV, ICA-BH and ICA-BU families. We thus analyzed microsatellites throughout the genome for the samples sequenced (proband, father and mother). Figure S3 .
Haplotype analysis for c.-34+5G>C
SNPs were genotyped with an Affymetrix 6.0 chip. After quality control (including a call rate of 100%), 909,622 SNPs were retained. Genotypes were phased with SHAPEIT v2 (38) software, with the 1000 Genomes samples as a reference panel. Familial information was used to improve the phasing and to identify the paternal haplotypes in which the mutation was located. We then determined the shared haplotype around the mutation and applied the likelihood-based ESTIAGE method (19) to estimate the age of the most recent common ancestor (MRCA) for the mutation. Recombination rates and haplotype frequencies were provided by the HapMap Project.
Prediction of the impact of 5'UTR mutations on mRNA structure
We used the NNsplice 9.0 tool (http://www.fruitfly.org/cgi-bin/seq_tools/splice.pl) (20) to assess the potential impact on splicing of the rare variants at the exon1/intron1 splice junction identified in three kindreds with ICA. This tool has been shown to perform well for predicting the impact of variants leading to a splicing defect (https://github.com/counsylresearch/posters/raw/ghpages/2017/ASHG/Q506C_Tran_Intronic_Variants_V1_Final_PRINT.pdf).
RPSA structure and modeling of the mutations
The structural data were obtained by mapping the positions of the human mutations onto the human crystal structure of the small ribosomal subunit (Entry #6EK0) (17) . All structural analyses and illustrations were made using PyMOL Molecular Graphics System, v.1.8 (Schrödinger).
RNAseq
Total cellular RNA was isolated from PBMCs with the RNeasy Mini kit (QIAGEN®).
Multiplexed RNA libraries were prepared with the Truseq RNA sample prep kit (Illumina®).
In brief, poly(A)-containing mRNAs were captured with oligodT beads, fragmented, reverse-transcribed, and the cDNA was ligated to Illumina adapters containing indexing barcodes. Libraries were quantified with KAPA Library Quant kits (KAPA Biosystems), and run on a HiSeq 2000 Sequencing System (Illumina) to produce 150 bp single-end reads.
Reads were then mapped with STAR v2.5.3a. Sashimi plots were generated with IGV (Broad Institute), using a minimum threshold of 20 reads for a splice event to be taken into account. The RNAseq dataset used will be available here: 
